ArticleDiabetology & metabolic syndrome2023
HbA1c is a predictive factor of severe coronary stenosis and major adverse cardiovascular events in patients with both type 2 diabetes and coronary heart disease.
Article in Diabetology & metabolic syndrome, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Cardiovascular benefits of semaglutide: a systematic review and meta-analysis of randomized controlled trials.BMC cardiovascular disorders · 2025 · on this mapPooled it
- Predicting lower extremity deep vein thrombosis in elderly patients with hip fracture: A machine learning model with emphasis on diabetes as a key risk factor.Experimental and therapeutic medicine · 2026Article
- Association Between Triglyceride/High-Density Lipoprotein Ratio and Premature Coronary Artery Disease in Young Saudi Population: A Case-Control Study.Diagnostics (Basel, Switzerland) · 2026Article
- An online interpretable machine learning model for predicting cardiometabolic multimorbidity risk in patients with type 2 diabetes mellitus.Scientific reports · 2026Article
- Analysis of risk factors for heart failure in patients with type 2 diabetes mellitus and acute ST-segment elevation myocardial infarction after percutaneous coronary intervention.Frontiers in medicine · 2026Article
- Relationship between hemoglobin glycation index and all-cause mortality in patients with acute myocardial infarction: based on MIMIC-IV database.Diabetology & metabolic syndrome · 2025Article
- Advances in Molecular Mechanisms and Precision Interventions of Cardiovascular Injuries Related to Glucose and Lipid Metabolism Disorders.Reviews in cardiovascular medicine · 2025Review
- Prognostic significance of HANBAH score in evaluating mortality and major adverse cardiovascular events in patients with diabetes mellitus.BMC cardiovascular disorders · 2025Article
- Incorporating genetic data improves target trial emulations and informs the use of polygenic scores in randomized controlled trial design.Nature genetics · 2025Article
- More schooling is associated with lower hemoglobin A1c at the high-risk tail of the distribution: an unconditional quantile regression analysis.BMC public health · 2025Article
- Prevalence of macro-vascular complications among type 2 diabetic adults aged 50 and over: results from Ardakan cohort study on aging (ACSA).Journal of diabetes and metabolic disorders · 2025Article
- Association between glycated hemoglobin and cognitive impairment in older adults with coronary heart disease: a multicenter prospective cohort Study.Journal of geriatric cardiology : JGC · 2025Article
- Article
- A Narrative Review of the Role of Blood Biomarkers in the Risk Prediction of Cardiovascular Diseases.Cureus · 2024Review
- U-shaped association between HbA1c and all-cause mortality in CVD patients with diabetes.Scientific reports · 2024Article
- Article
- Glycemic Control and Cardiometabolic Risk in Black Zimbabweans with Type 2 Diabetes Mellitus.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Article
- Predictive power of glycated hemoglobin in detecting severity of coronary artery disease in non-diabetic patients: A cross-sectional study in southern Iran.ARYA atherosclerosis · 2024Article
- Glycation in the cardiomyocyte.Vitamins and hormones · 2024Review
- The Impact of Dyslipidemia on the Clinical Profile of Patients With Uncontrolled Diabetes.In vivo (Athens, Greece)Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 2 countries.
Funding
Abstract
backgroundCoronary heart disease (CHD) is not only a macrovascular complication of type 2 diabetes mellitus (T2DM). Cardiovascular disease (CVD) is one of the leading causes of mortality among individuals with T2DM. Reducing the risk of adverse cardiovascular events (MACE) is crucial for the management of patients with CHD. This study aimed to investigate the effect of glycemic control on CHD severity and 3-point MACE (3p-MACE) risk in patients with T2DM and CHD.
methods681 patients with both T2DM and CHD throughout October 2017 and October 2021 who were hospitalized in the second affiliated hospital of Nanchang university were included. A total of 300 patients were eventually enrolled in this retrospective cohort research. The severity of CHD in these patients was assessed, and the primary outcome during follow-up was recorded, with the primary result being the 3-point major adverse cardiovascular event (3p-MACE). The correlation between baseline glycated hemoglobin A1c (b-HbA1c) and the severity of CHD was evaluated by logistic regression analysis. The effect of b-HbA1c and follow-up HbA1c (f-HbA1c) levels on the risk of 3p-MACE were investigated by cox regression analysis.
resultsb-HbA1c was positively correlated with the severity of CHD (r = 0.207, p = 0.001), and patients with b-HbA1c > 9% were more likely to have severe CHD. The HRs for b-HbA1c and f-HbA1c on the risk of 3p-MACE were 1.24 (95% CI 0.94-1.64, p = 0.123) and 1.32 (95% CI 1.02-1.72, p = 0.036), respectively. Patients with f-HbA1c ≥8.6% had a higher risk of 3p-MACE than f-HbA1c < 8.6% (HR = 1.79, 95% CI 1.16-2.79, p = 0.009).
conclusionIn patients with both T2DM and CHD, b-HbA1c was an independent predictive factor of severe CHD. f-HbA1c was an independent predictive factor of 3p-MACE. Having the f-HbA1c below 8.6% significantly reduced the risk of 3p-MACE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.